Allakos Inc. (ALLK)

1.0100 0.0000 (0.00%) As of 10:58AM EDT. Market open.

Allakos Inc.

825 Industrial Road
Suite 500
San Carlos, CA 94070
United States
650 597 5002
https://www.allakos.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 131

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Robert Alexander Ph.D.	CEO & Director	1.5M	N/A	1970
Dr. Adam L. Tomasi Ph.D.	President	1.15M	N/A	1970
Mr. Baird Radford III	Chief Financial Officer	731.35k	N/A	1970
Ms. Mary Cromwell Ph.D.	Chief Technical Officer	N/A	N/A	N/A
Mr. Alan Chang	Director of Medical Affairs & Data Analytics	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Corporate governance

Allakos Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.